Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-17-335713
Filing Date
2017-11-07
Accepted
2017-11-07 16:02:35
Documents
1
Group Members
BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.BAY CITY CAPITAL LLCBAY CITY CAPITAL MANAGEMENT V LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 TO SCHEDULE 13D d482433dsc13da.htm SC 13D/A 104151
  Complete submission text file 0001193125-17-335713.txt   105979
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Subject) CIK: 0001061027 (see all company filings)

EIN.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-81034 | Film No.: 171183345
SIC: 2834 Pharmaceutical Preparations

Mailing Address 750 Battery Street Suite 400 San Francisco CA 94111
Business Address 750 Battery Street Suite 400 San Francisco CA 94111 415-676-3830
Bay City Capital Fund V, L.P. (Filed by) CIK: 0001401826 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A